Member Info for crumbs

Scancell is not looking to be bought out at this stage... why would they? ... like I said a proven moditope takes us in to the stratosphere of a new revolutionary market.... modi1 trial expected to begin this year

If Drack bought 100k blindly here without a clue about scancell..... what does that say about his VAL investment lol...

The kinds of money a scancell with a proven moditope platform would be looking at in any buy out would be Kite pharma and Juno figures so that is $11.9 billion and $9 billion though considering scancells landgrab patent means no one else can get in on the moditope mechanism scancell would be worth more than those two combined.... think you need to concentrate on IO techs and their values... how valuable is Keytruda to Merk?... a product who's mechanism no one company owns the IP on...

It works...The question is % as Lindy says will it be exceptional will it be small we hope it will be significant.....But the preclinical extensive work shows it is an existing mechanism it works...... sahin been let in already and karolinska and their going nowhere....Watch the space Astra's move interesting

Yes it is not about current market and what share you could have it is about having a whole new market of the currently untreatable... It's huge....Need the trial first though

Hopefully all commercial and in many targets yeah

Add in modi2 and glycans...

Astra deal very interesting... considering they just dumped at great cost a big part of their IO pipeline... is this a good move for them? well it is an early stage product...I'd say they have taken quite a risk... but just goes to show the potential value of what scancell has... modi1- 17 targets and that is just modi1!

'About Trastuzumab deruxtecan

Trastuzumab deruxtecan (DS-8201; [fam-] trastuzumab deruxtecan in US only) is the lead potential new medicine in the ADC franchise of the Daiichi Sankyo Cancer Enterprise. ADCs are targeted cancer medicines that deliver cytotoxic agents to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells.

A broad and comprehensive development programme with trastuzumab deruxtecan is underway in North America, Europe and Asia, including five pivotal trials in HER2-expressing breast and gastric cancers. Trastuzumab deruxtecan is also in Phase II development for HER2-expressing advanced colorectal cancer and metastatic non-squamous HER2-overexpressing or HER2-mutated NSCLC, and Phase I development in combination with nivolumab for HER2-expressing metastatic breast and bladder cancers.

Trastuzumab deruxtecan was granted Breakthrough Therapy Designation in 2017 by the US FDA for the treatment of patients with HER2-positive, locally-advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after trastuzumab emtansine. Fast Track Designation was also granted in the US for the treatment of HER2-positive unresectable and/or metastatic breast cancer in patients who have progressed after prior treatment with HER2-targeted medicines, including trastuzumab emtansine. Trastuzumab deruxtecan has received Sakigake designation for the treatment of HER2-positive advanced gastric or gastroesophageal junction cancer by the Japan Ministry of Health, Labour and Welfare.

Trastuzumab deruxtecan is a potential new medicine that has not been approved for any indication in any country. Safety and efficacy have not been established.'

It all depends on how the research collab is going.. last we heard it is going great and that we took on Sam to spearhead the 'new TCR therapeutics' says it all really... you would think deal talks have been ongoing along with the lab progress.. surely we are in an interesting time even if it feels like treading water :)

Chester page 10... of course, scancell timelines are never to be taken too literally :)

https://www.scancell.co.uk/file-manager/PDFs/scancell-presentation-feb18v2.pdf

Shhh, a trade is about to go through........ oh no it was just tumbleweed :)

Plus there isn't really anything new to post about :)

Or buy land on the Faroes and a harpoon

Also on deals... when you send all those under NDA an oh by the way Sahin has after a year and half of having worked with it done a deal with us on modi1 for TCR... they suddenly start saying a bit more than just 'thanks and keep us informed' lol...

Also by now I really think scancell will know is the money going to last before we get a deal... they surely know how close the TCR one is or isn't (Samantha spearheading the new TCR therapeutics' ... so if they know the money will run out and no deal is coming I'd reckon a raising before Sept myself... they would want to do it after IND and SCIB1 in trial so with a hopefully higher sp... as with everything it's a wait and see... like being in a never-ending soviet era bread queue :)

I've read a bit about how the kinds of deals scancell are after are done... now I have no doubt scancell have NDAs with probably tens of pharma and biotechs... lots of really big names no doubt... and that for instance last weeks patent news will have been relayed to them all and that arrival of modi2 etc and all progress is reported to them and that they probably reply thanks and please keep us informed... The difference is you need someone at a company who 'gets it' and not just that but 'wants it' that is how the deals are really done... ImmunoBody got interest and it seems close to a deal but it did not attract someone at the top who really wanted in on it!....Moditope... 'Ugur Sahin' and 'Ira Mellman' both men who could give the kinds of green lights that transform scancell and both are 'very excited' by moditope...and those are just the two we know about... we saw Astra have a very expensive clearout on their IO pipeline recently there is a real hunger for assets in IO and can anyone show any platform elsewhere with anything near the potential of moditope?

The point about the big sells and no doubts there have been big sells and we know about City selling etc... all I was meaning if it were pi selling those amounts you would expect a much lower sp... so maybe some many even who knows of those shares are simply changing hands... of course we all agree the trend here is ever downwards until a commercial deal or no dilutive fundraising ... both very possible with supporting evidence (e.gBioNtech TCR ) but impossible to time accurately so we are left with one fundamental which is the money is running out and the costs if/when trials do hallelujah begin will only go up... as ever potential of big rewards (scancells pipeline could dominate the future revolutionary Immuno market) but shadowed by constant risk of lower sp funding and dilution to get anywhere...

I said we will see.... so lets see

You have
Mays Deal
No deal
New deal... after a general election..
Remain

Remain to win by 60%... but hey!... we will see who knows... it is harder to predict than scancells next RNS

I've been wrong about all my scancell timeline predictions for 2019 so far but still think on Brexit.. a second referendum by what did I put July?... anyways we will see lol... I'd have prefered my scancell ones to be right though... come on team scancell!